Clovis Oncology (CLVS) Tops Q1 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Clovis Oncology Announces First Quarter 2017 Operating Results
May 3, 2017 4:05 PM EDTStrong Q1 launch quarter for Rubraca® (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3 target progression events achieved in mid-April Top-line ARIEL3 data anticipated by end of June Multiple clinical trials initiated in early 2017, including TRITON2 and TRITON3 in prostate cancer and Roche-sponsored rucaparib-atezolizumab combination study in gynecologic cancers Rucaparib E.U. Marketing Authorization Application under review; establishing E.U. organization to support potential Q1 2018 European launch... More
